PT Kalbe Farma Tbk (PTKFY)
OTHER OTC:PTKFY
Top Page
PT Kalbe Farma Tbk
(OTC:PTKFY)
Select Model
Select Model
Rating:67Neutral
Price Target:
$12.50
▼(-14.73% Downside)
Action:ReiteratedDate:04/04/26
The score is driven primarily by strong financial quality (especially a low-risk balance sheet and consistent profitability/FCF). This is meaningfully offset by weak technicals (price below key moving averages with negative MACD) and only moderate valuation support (good dividend yield but a mid-range P/E).
Positive Factors
Conservative balance sheet
Very low leverage and a growing equity base give Kalbe durable financial flexibility. This reduces solvency risk, supports continued R&D, capex, and dividend capacity, and allows the company to absorb shocks or pursue selective M&A without stressing cash flows over the next several quarters.
Negative Factors
Slowing revenue growth
Decelerating top-line expansion signals maturation or increasing competitive pressure in key segments. Slower revenue growth reduces operating leverage and limits scope to expand margins or reinvest at prior rates, constraining EPS and return improvement over the coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage and a growing equity base give Kalbe durable financial flexibility. This reduces solvency risk, supports continued R&D, capex, and dividend capacity, and allows the company to absorb shocks or pursue selective M&A without stressing cash flows over the next several quarters.
Read all positive factors
PT Kalbe Farma Tbk (PTKFY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.61B
Dividend Yield3.33%
Average Volume (3M)154.00
Price to Earnings (P/E)13.9
Beta (1Y)0.54
Revenue Growth3.32%
EPS Growth11.04%
CountryUS
Employees12,841
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)0.27
Shares Outstanding234,066,960
10 Day Avg. Volume0
30 Day Avg. Volume154
Financial Highlights & Ratios
PEG Ratio0.91
Price to Book (P/B)2.19
Price to Sales (P/S)1.45
P/FCF Ratio20.78
Enterprise Value/Market Cap15.52K
Enterprise Value/Revenue1.15
Enterprise Value/Gross Profit2.91
Enterprise Value/Ebitda7.65
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PT Kalbe Farma Tbk Business Overview & Revenue Model
Company Description
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribu...
How the Company Makes Money
Kalbe Farma primarily makes money by selling healthcare products and related services across four main business divisions: (1) Prescription Pharmaceuticals: revenue is generated from the sale of prescription medicines (including branded and generi...
PT Kalbe Farma Tbk Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
90
Very Positive
Cash Flow
72
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 35.32T | 32.63T | 30.45T | 28.93T | 26.26T |
| Gross Profit | 14.06T | 12.96T | 11.82T | 11.70T | 11.28T |
| EBITDA | 5.18T | 4.61T | 4.02T | 5.25T | 4.87T |
| Net Income | 3.66T | 3.24T | 2.77T | 3.38T | 3.18T |
Balance Sheet | |||||
| Total Assets | 30.70T | 29.43T | 27.06T | 27.24T | 25.67T |
| Cash, Cash Equivalents and Short-Term Investments | 4.49T | 4.87T | 3.40T | 4.10T | 6.48T |
| Total Debt | 297.28B | 559.22B | 618.54B | 1.17T | 626.16B |
| Total Liabilities | 5.97T | 4.84T | 3.94T | 5.14T | 4.40T |
| Stockholders Equity | 23.31T | 22.79T | 21.42T | 20.39T | 19.58T |
Cash Flow | |||||
| Free Cash Flow | 2.46T | 3.53T | 1.73T | 2.90T | 1.83T |
| Operating Cash Flow | 3.27T | 4.79T | 2.91T | 3.77T | 2.83T |
| Investing Cash Flow | -799.89B | -1.25T | -1.14T | -1.37T | -1.06T |
| Financing Cash Flow | -2.87T | -2.09T | -2.44T | -2.41T | -745.18B |
PT Kalbe Farma Tbk Technical Analysis
Negative
14.66
Price Trends
12.39
Negative
13.41
Negative
14.70
Negative
Market Momentum
-0.32
Negative
35.26
Neutral
29.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PTKFY, the sentiment is Negative. The current price of 14.66 is above the 20-day moving average (MA) of 11.53, above the 50-day MA of 12.39, and below the 200-day MA of 14.70, indicating a bearish trend. The MACD of -0.32 indicates Negative momentum. The RSI at 35.26 is Neutral, neither overbought nor oversold. The STOCH value of 29.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PTKFY.
PT Kalbe Farma Tbk Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $2.61B | 13.95 | 15.61% | 3.33% | 3.32% | 11.04% | |
52 Neutral | $1.59B | 9.95 | 25.50% | 4.80% | -1.69% | -61.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $6.54B | 14.03 | 7.56% | 1.56% | 9.45% | 167.00% | |
45 Neutral | $47.59M | -0.22 | 435.85% | ― | -8.12% | ― | |
45 Neutral | $58.61M | -3.95 | -55.19% | ― | ― | ― |
* Healthcare Sector Average
PTKFY
PT Kalbe Farma Tbk
11.12
-1.80
-13.93%
GRFS
Grifols SA
8.10
1.26
18.42%
SRXH
SRx Health Solutions
0.16
-1.49
-90.36%
SCLX
Scilex Holding Company
7.02
-1.28
-15.42%
OGN
Organon
6.12
-6.40
-51.11%
CTOR
Citius Oncology
0.66
0.03
5.24%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.